These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1721888)

  • 1. [Conservative therapy of prostate cancer].
    Leitenberger A; Altwein JE
    Fortschr Med; 1991 Sep; 109(28):563-7. PubMed ID: 1721888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic options in advanced cancer of the prostate].
    Schmid HP; Bitton A
    Praxis (Bern 1994); 1997 Oct; 86(44):1734-9. PubMed ID: 9446174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
    Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
    J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
    Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
    Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence.
    Ginzburg S; Albertsen PC
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):615-23, ix. PubMed ID: 21889724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostatic cancer in the male under age 60].
    Maier U; Nuehold N
    Wien Klin Wochenschr; 1988 Sep; 100(17):577-9. PubMed ID: 3188531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
    J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radical prostatectomy and adjuvant endocrine treatment of prostatic cancer with lymphatic metastasis?].
    Schröder FH
    Urologe A; 1991 Nov; 30(6):417-22. PubMed ID: 1722923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The potential hormonal therapy of prostatic carcinoma].
    Studer UE; Altwein J; Bartsch G
    Urologe A; 1991 Sep; 30(5):310-6. PubMed ID: 1949440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical protocols in treatment of prostatic carcinoma in Europe. The role of EORTC and other organizations].
    Newling DW
    Urologe A; 1995 Sep; 34(5):374-81. PubMed ID: 7483153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Possibilities in drug therapy in prostatic carcinoma].
    Schmid HP
    Ther Umsch; 1995 Jun; 52(6):418-22. PubMed ID: 7541571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.